The global digital biomarkers market is projected to be worth over USD 22 billion by 2030
Roots Analysis has done a detailedstudy on “Digital Solutions forBiomarkers Market, 2021-2030” covering key aspects of the industry’sevolution and identifying potential future growth opportunities.
To order this 270+ page report, which features135+ figures and 140+ tables, please visit https://www.rootsanalysis.com/reports/digital-biomarkers-market.html
Key Market Insights
§ Presently, over 30 players are engaged in thedevelopment of digital solutions for different types of biomarkers; thesesolutions can be analyzed in silico, for a variety of diseases /clinical conditions
§ The pipeline features a variety of digitalsolutions, which are being evaluated across different stages of development,designed to identify and analyze a diverse set of biomarkers, for use across arange of indications
§ In order to maintain a competitive edge,companies engaged in the development of digital solutions for biomarkers arepresently focusing on the integration of advanced features into theirrespective product offerings
§ In the short to mid-term, considering theirapplicability across more than 35 target indications, more solutions forphysiological / vocal biomarkers are likely to be developed for patientdiagnosis / monitoring
§ Case Study: The gradual shift towards incorporation ofdigital health tools to overcome physical confines of clinical environment isevident from ~40 global events that have recently been organized for digitalbiomarkers
§ Foreseeing a lucrativefuture, several public and private investors have made investments worth aroundUSD 1 billion, across over 110 publicly reported funding instances
§ The growing interestof stakeholders is also evident from the rise in partnership activity withinthis domain; in fact, the maximum number of collaborations related to digitalsolutions for biomarkers were inked in 2020
§ In order to tap intothe lucrative opportunity associated with these modern solutions, several bigpharma players have also undertaken diverse initiatives in this field, rangingfrom product development to strategic investments
§ The market for digital solutions forbiomarkers is expected to witness growth at an annualized rate of about 32%,from 2021-2030, with revenues from product sales coming in via both B2B and B2Cchannels
§ The projected future opportunity for companiesengaged in this field is expected to be well distributed across differenttherapeutic areas, purposes of solutions, and key geographical regions
For more information, please visit https://www.rootsanalysis.com/reports/digital-biomarkers-market.html
Tableof Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1 Chapter Overview
3.2. Digitization in the Healthcare Sector
3.3. Next-Generation Healthcare Solutions
ChapterOverview
3.2. Overview of Digital Biomarkers
3.2.1 Classification of Digital Biomarkers
3.2.2 Key Advantages and Limitations
3.3. Digital Biomarker-related ProductDevelopment and Commercialization Path
3.3.1. Product Discovery and Development
3.3.2. Validation and Regulatory Submissions
3.3.3. Distribution and Marketing
3.4. Prevalent Trends Related to DigitalBiomarkers
3.4.1. Emerging Focus Areas
3.4.2. Key Historical Trends
3.4.3. Geographical Activity
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Solutions for Biomarkers: OverallMarket Landscape
4.2.1. Analysis by Current Status
4.2.2. Analysis by Content of Solution
4.2.3. Analysis by Purpose of Solution
4.2.4. Analysis by Type of Biomarker
4.2.5. Analysis by Target Indication(s)
4.2.6. Analysis by Therapeutic Area
4.2.7. Analysis by Target Population
4.2.8. Analysis by Prescription Requirement
4.3. Digital Solutions for Biomarkers:Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Business Model Used
4.3.4 Analysis by Location of Headquarters
4.4. Leading Developers: Analysis by Number ofDigital Solutions for Biomarker
4.5. Digital Solutions for Biomarkers:Information on Additional Players
5. KEY INSIGHTS
5.1. Chapter Overview
5.2. 4D Bubble Analysis: Analysis by PortfolioStrength, Type of Biomarker and Company Size
5.3. Grid Representation: Analysis by CurrentStatus, Content of Solution and Therapeutic Area
5.4. Treemap Representation: Analysis byTherapeutic Area and Company Size
5.5. World Map Representation: Analysis byLocation of Headquarters
5.6. Current and Future Market LandscapeTrends Analysis
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Acculi Labs
6.2.1 Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. Canary Health Technologies
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Empatica
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook
6.5 IXICO
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Kinsa
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Progentec Diagnostics
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook
6.8. Vocalis Health
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3 Recent Developments and Future Outlook
7. PRODUCT COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Key Parameters and Methodology
7.3. Product Competitiveness Analysis
7.3.1. Product Competitiveness Analysis:Idiosyncratic Biomarkers
7.3.2. Product Competitiveness Analysis:Physiological Biomarkers
7.3.3. Product Competitiveness Analysis: VocalBiomarkers
7.3.4. Product Competitiveness Analysis: OtherBiomarkers
8. GLOBAL EVENTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Global Events Related to DigitalBiomarkers
8.3.1. Analysis by Year of Occurrence
8.3.2. Analysis by Event Platform
8.3.3. Analysis by Geography
8.3.4. Analysis by Type of Event
8.3.5. Evolutionary Trend in Key Agenda / EventAgenda
8.3.6. Most Active Event Organizers
8.3.7. Most Active Players in Terms of EventParticipation
8.3.8. Analysis by Seniority Level of Participants
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Digital Solutions for Biomarkers: Fundingand Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Type of Biomarker
9.3.5. Analysis by Therapeutic Area
9.3.6. Analysis by Geography
9.3.7. Most Active Players: Analysis by Number ofInstances
9.3.8. Most Active Players: Analysis by AmountInvested
9.3.9. Most Active Investors: Analysis by Number ofInstances
9.4 Concluding Remarks
10. PARTNERSHIPS AND COLLABORATIONS
10.1. Chapter Overview
10.2. Partnership Models
10.3. Digital Solutions for Biomarkers: RecentPartnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.2.1Analysis by Type of Partnership and Year of Partnership
10.3.2.2Analysis by Type of Partnership and Company Size
10.3.3. Analysis by Type of Partner
10.3.3.1.Analysis by Type of Partner and Year of Partnership
10.3.3.2.Analysis by Type of Partner and Type of Partnership
10.3.3.3.Analysis by Type of Partner and Company Size
10.3.4. Analysis by Type of Biomarker
10.3.4.1.Analysis by Type of Biomarker and Year of Partnership
10.3.4.2.Analysis by Type of Biomarker and Type of Partnership
10.3.5. Analysis by Therapeutic Area
10.3.5.1.Analysis by Therapeutic Area and Year of Partnership
10.3.5.2.Analysis by Therapeutic Area and Type of Partner
10.3.6. Most Active Players: Analysis by Number ofPartnerships
10.3.7. Regional Analysis
10.3.8. Intercontinental and IntracontinentalAgreements
11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Digital Biomarker-related Initiatives ofBig Pharma Players
11.3.1. Clinical Research Activity
11.3.2. Partnership Activity
11.3.3. Funding and Investments
11.3.4. Participation in Global Events
11.3.5. Research Publications
11.4. Benchmark Analysis of Big PharmaceuticalPlayers
11.4.1. Spider Web Analysis: Company A
11.4.2. Spider Web Analysis: Company B
11.4.3. Spider Web Analysis: Company C
11.4.4. Spider Web Analysis: Company D
11.4.5. Spider Web Analysis: Company E
11.4.6. Spider Web Analysis: Company F
11.4.8. Spider Web Analysis: Company G
11.4.8. Spider Web Analysis: Company H
11.4.9. Spider Web Analysis: Company I
11.4.10.Spider Web Analysis: Company J
11.4.11.Spider Web Analysis: Company K
11.4.12.Spider Web Analysis: Company L
11.4.13.Spider Web Analysis: Company M
12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Digital Solutions for Biomarkers Market,2021-2030
12.4. Digital Solutions for Biomarkers Market:Distribution by Content of Solution
12.4.1. Digital Solutions for Biomarkers Marketfor Standalone Software Applications, 2021-2030
12.4.2. DigitalSolutions for Biomarkers Market for Combination Offering (Software Application+ AI Support), 2021-2030
12.4.3. DigitalSolutions for Biomarkers Market for Combination Offering (Software Application+ Device), 2021-2030
12.4.4. DigitalSolutions for Biomarkers Market for Combination Offering (Software Application+ AI Support + Device), 2021-2030
12.4.5. Digital Solutions for Biomarkers Marketfor Other Content of Solutions, 2021-2030
12.5. Digital Solutions for Biomarkers Market:Distribution by Purpose of Solution
12.5.1. Digital Solutions for Biomarkers Marketfor Diagnosis, 2021-2030
12.5.2. Digital Solutions for Biomarkers Marketfor Early Screening, 2021-2030
12.5.3. Digital Solutions for Biomarkers Marketfor Monitoring, 2021-2030
12.5.4. Digital Solutions for Biomarkers Marketfor Predictive Insights, 2021-2030
12.6. Digital Solutions for Biomarkers Market:Distribution by Type of Biomarker
12.6.1. Digital Solutions for Cognitive BiomarkersMarket, 2021-2030
12.6.2. Digital Solutions for IdiosyncraticBiomarkers Market, 2021-2030
12.6.3. Digital Solutions for PhysiologicalBiomarkers Market, 2021-2030
12.6.4. Digital Solutions for Vocal BiomarkersMarket, 2021-2030
12.6.5. Digital Solutions for Other BiomarkersMarket, 2021-2030
12.7. Digital Solutions for Biomarkers Market:Distribution by Therapeutic Area
12.7.1. Digital Solutions for Biomarkers Marketfor Autoimmune Disorders, 2021-2030
12.7.2. Digital Solutions for Biomarkers Marketfor Cardiovascular Disorders, 2021-2030
12.7.3. Digital Solutions for Biomarkers Marketfor Infectious Disorders, 2021-2030
12.7.4. Digital Solutions for Biomarkers Marketfor Mental Health Problems, 2021-2030
12.7.5. Digital Solutions for Biomarkers Marketfor Neurological Disorders, 2021-2030
12.7.6. Digital Solutions for Biomarkers Marketfor Respiratory Disorders, 2021-2030
12.7.7. Digital Solutions for Biomarkers Marketfor Substance Use Disorders, 2021-2030
12.7.8. Digital Solutions for Biomarkers Marketfor Other Disorders, 2021-2030
12.8. Digital Solutions for Biomarkers Market:Distribution by Business Model
12.8.1. DigitalSolutions for Biomarkers Market for B2B Model (Healthcare Providers, Payers,Employers and Pharmaceutical Companies), 2021-2030
12.8.2. DigitalSolutions for Biomarkers Market for B2C Model (Patients and Caregivers),2021-2030
12.9. Digital Solutions for Biomarkers Market:Distribution by Key Geographical Regions
12.9.1. Digital Solutions for Biomarkers Marketin North America, 2021-2030
12.9.2. Digital Solutions for Biomarkers Market inEurope, 2021-2030
12.9.3. Digital Solutions for Biomarkers Marketin Asia-Pacific, 2021-2030
12.9.4. DigitalSolutions for Biomarkers Market in Middle East and North Africa (MENA),2021-2030
12.9.5. Digital Solutions for Biomarkers Marketin Rest of the World, 2021-2030
12.10. Concluding Remarks
13. IMPACT OF COVID-19 PANDEMIC ON DIGITALSOLUTIONS FOR BIOMARKERSMARKET
13.1. Chapter Overview
13.2. Impact of COVID-19 Pandemic on DigitalSolutions for Biomarkers Market
13.2.1. Impact on Future Market Opportunity forDigital Solutions for Biomarkers
13.3. Current Opinions and Key Initiatives of KeyPlayers
13.4. Recuperative Strategies for DeveloperBusinesses
13.4.1. Strategies for Implementation in the Short /Mid Term
13.4.2. Strategies for Implementation in the Long Term
14. CONCLUSION
14.1. Chapter Overview
14.2. Key Takeaways
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Tilak Healthcare
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Edouard Gasser,Co-Founder and Chief Executive Officer
15.3. Vocalis Health
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Michael Seggev, ChiefCommercial Officer
16. APPENDIX I: TABULATED DATA
17. APPENDIX II: LIST OF COMPANIES ANDORGANIZATION
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
